Reuters Health Report: November 1, 2017

Click to View in Browser Wednesday, November 1, 2017 Indivior drug to fight opioid addiction recommended by U.S. panel (Reuters) - Indivior's experimental drug to help fight America's growing opioid addiction crisis has been recommended for approval by a U.S. advisory panel, boosting its sales prospects as competitors threaten revenues from an older product. New Jersey sues OxyContin maker, links marketing to opioid crisis (Reuters) - New Jersey on Tuesday sued Purdue Pharma LP, accusing the maker of the chronic pain medication OxyContin of fueling the state's opioid crisis through deceptive marketing to doctors and patients, including the elderly and the "opioid-naive." AstraZeneca asthma drug tralokinumab disappoints again LONDON (Reuters) - An experimental biotech drug for severe asthma from AstraZeneca has failed in further clinical tests, following an earlier setback in May and disappointing results with a similar drug at Roche. U.S. states allege broad generic drug price-fixing collusion WASHINGTON (Reuters) - A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling. U.S. experts set research agenda to meet 'Cancer Moonshot' goals CHICAGO (Reuters) - It will take a major shift in the way cancer research is done in the United States to meet the ambitious goals set out by the U.S. Cancer Moonshot, researchers said on Tuesday. U.S. court bars Philips from selling some defibrillators WASHINGTON (Reuters) - A federal court barred Philips North America LLC and two of its executives from distributing certain medical devices, including some of the company's external defibrillators, until the company takes remedial steps, the Department of Justice said on Tuesday. AstraZeneca wins early U.S. approval for blood cancer drug LONDON (Reuters) - AstraZeneca has won U.S. approval for a new blood cancer drug several months earlier than expected, boosting its oncology portfolio - and requiring it to pay $1.5 billion to shareholders in the biotech company that first discovered the medicine. Can spicy foods curb salt cravings or lower blood pressure? (Reuters Health) - People who like spicy foods may eat less salt and have lower blood pressure, potentially reducing their risk of heart attacks and strokes, a study from China suggests. Bayer, Novartis clash with UK doctors over use of cheap eye drug LONDON (Reuters) - Bayer is weighing legal action and Novartis has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug. UK's NICE gives Roche drug green light for bladder cancer LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer. Related Video Robotic eel seeks out water pollution Recycling charity gets creative with trash diverted from landfill A quick-fix on the day's news delivered when you want it. Register Today A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today » » MORE NEWSLETTERS - 3 Times Square New York, NY 10036 USA © Copyright 2017 Thomson Reuters Ensure delivery of Reuters Newsmails, add newsletters@email.reuters.com to your address book. Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook